SecBot SecBot
SECBOTREPLAY Home › Report › BNTX

BNTX · BioNTech reported Q3 2026 revenue of €1,289.2M, beating the €1,040M…

BioNTech SE · PRESS-RELEASE filed Nov 3, 2026 at 06:45 ET

At the news

NEUTRALIMPACT 5/10

PRESS-RELEASE filed Nov 3, 2026 at 06:45 ET

BioNTech reported Q3 2026 revenue of €1,289.2M, beating the €1,040M consensus, and GAAP diluted EPS of €0.73, slightly below the $0.76 consensus. The company raised its full-year 2026 revenue guidance midpoint to €1.7-1.9 billion from €1.6-1.9 billion, driven by COVID-19 vaccine sales, while maintaining its oncology pipeline investments.

  • Q3 2026 revenue €1,289.2M vs consensus €1,040M (beat)
  • GAAP diluted EPS €0.73 vs consensus $0.76 (miss by ~4%)
  • Full-year 2026 revenue guidance raised to €1.7-1.9 billion from €1.6-1.9 billion
  • Adjusted R&D expenses €578.5M, within unchanged guidance of €2.0-2.3 billion

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access